Jazz Pharmaceuticals Plc (JAZZ)
244.54
-6.56
(-2.61%)
USD |
NASDAQ |
Aug 28, 16:00
244.58
+0.04
(+0.02%)
After-Hours: 20:00
Jazz Pharmaceuticals Free Cash Flow : 1.508B for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.508B |
| March 31, 2026 | 1.186B |
| December 31, 2025 | 1.189B |
| September 30, 2025 | 1.282B |
| June 30, 2025 | 1.240B |
| March 31, 2025 | 1.488B |
| December 31, 2024 | 1.358B |
| September 30, 2024 | 1.130B |
| June 30, 2024 | 1.045B |
| March 31, 2024 | 1.011B |
| December 31, 2023 | 1.068B |
| September 30, 2023 | 1.243B |
| June 30, 2023 | 1.363B |
| March 31, 2023 | 1.363B |
| December 31, 2022 | 1.218B |
| September 30, 2022 | 1.053B |
| June 30, 2022 | 878.07M |
| March 31, 2022 | 621.83M |
| December 31, 2021 | 732.98M |
| September 30, 2021 | 711.34M |
| June 30, 2021 | 708.02M |
| March 31, 2021 | 750.33M |
| December 31, 2020 | 520.39M |
| September 30, 2020 | 454.90M |
| June 30, 2020 | 478.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 508.65M |
| December 31, 2019 | 594.07M |
| September 30, 2019 | 732.60M |
| June 30, 2019 | 681.32M |
| March 31, 2019 | 644.12M |
| December 31, 2018 | 661.03M |
| September 30, 2018 | 629.51M |
| June 30, 2018 | 518.42M |
| March 31, 2018 | 573.38M |
| December 31, 2017 | 579.14M |
| September 30, 2017 | 570.87M |
| June 30, 2017 | 580.97M |
| March 31, 2017 | 429.49M |
| December 31, 2016 | 408.95M |
| September 30, 2016 | 345.91M |
| June 30, 2016 | 400.18M |
| March 31, 2016 | 554.27M |
| December 31, 2015 | 495.98M |
| September 30, 2015 | 700.48M |
| June 30, 2015 | 577.12M |
| March 31, 2015 | 511.37M |
| December 31, 2014 | 369.42M |
| September 30, 2014 | 124.65M |
| June 30, 2014 | 205.73M |
| March 31, 2014 | 149.09M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Avadel Pharmaceuticals Plc | -- |
| Perrigo Co. Plc | 119.30M |
| GH Research Plc | -52.46M |
| Cosmo NV | -29.99M |
| Axsome Therapeutics, Inc. | -71.96M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 415.70M |
| Cash from Investing (Quarterly) | 354.90M |
| Cash from Financing (Quarterly) | -994.50M |
| Free Cash Flow Per Share (Quarterly) | 5.729 |
| Free Cash Flow to Equity (Quarterly) | 1.405B |
| Free Cash Flow to Firm (Quarterly) | 454.65M |
| Free Cash Flow Yield | 9.47% |